A Baycol Strategy? Roche OTC Unit Gives Bayer Some Cash Flexibility For The Future
This article was originally published in The Pink Sheet Daily
Swiss OTC division gives Bayer a steady cash flow business that could limit exposure to liability associated with Baycol. Early estimates put charges at $1.6 bil. but could become significantly higher.
You may also be interested in...
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.
With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.
NASEM is expected to issue a highly anticipated report in early 2021 on solutions to address Rx vial drug wastage.